Snapshot from Jul 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / VERAXA Biotech, ATUM Collaborate on BiTAC-TCE
Business collaboration

VERAXA Biotech, ATUM Collaborate on BiTAC-TCE

Analysis based on 10 articles · First reported Jul 02, 2026 · Last updated Jul 02, 2026

Sentiment
60
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The collaboration between VERAXA Biotech AG and Atum is expected to positively impact the biotechnology sector, particularly in cancer therapies. VERAXA Biotech AG's stock (NASDAQ: VRXA) could see an increase due to the advancement of its BiTAC-TCE program towards clinical development, signaling progress in its pipeline and potential future revenue streams.

Biotechnology Pharmaceuticals
Event Summary

VERAXA Biotech AG, a leader in cancer therapies, announced on July 2, 2026, the initiation of cell line development for its lead BiTAC T-cell engager (BiTAC-TCE) program. This crucial step towards IND/CTA-enabling activities and future clinical development is being supported by Atum, a global leader in bioengineering and cell line development, utilizing its proprietary Leap-In Transposase technology. The BiTAC-TCE approach aims to address the toxicity limitations of conventional T-cell engagers by requiring simultaneous engagement of two distinct antigens for activation, thereby enhancing tumor selectivity and potentially widening the therapeutic window. Initial preclinical data for VERAXA Biotech AG's BiTAC-TCE program, presented at the American Association for Cancer Research Annual Meeting 2026, showed a superior safety profile and matching efficacy compared to traditional TCEs.

Key Actions
90 VERAXA Biotech AG initiated development
60 VERAXA Biotech AG presented data American Association for Cancer Research
Entities Involved
priv
VERAXA Biotech AG
VERAXA Biotech AG initiated cell line development for its lead BiTAC-TCE program with Atum, a crucial step towards clinical development and potential market entry for its cancer therapies.
Importance 100.0 Sentiment 70.0
per
Christoph Erkel
Christoph Erkel, VP Research & Development of VERAXA Biotech AG, commented on the importance of the collaboration with Atum for accelerating the BiTAC-TCE program.
Importance 20.0 Sentiment 0.0
ngo
American Association for Cancer Research
VERAXA Biotech AG presented initial data from its BiTAC-TCE program at the American Association for Cancer Research Annual Meeting 2026, providing a platform for scientific dissemination.
Importance 10.0 Sentiment 0.0
ngo
European Molecular Biology Laboratory
VERAXA Biotech AG was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, highlighting its scientific origins.
Importance 5.0 Sentiment 0.0
cnt
Switzerland
VERAXA Biotech AG AG is headquartered in Zurich, Switzerland.
Importance 0.0 Sentiment 0.0
cnt
United States
Atum is a US-based contract research organization.
Importance 0.0 Sentiment 0.0
Relationships
VERAXA Biotech AG related ↔ Christoph Erkel
Switzerland related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.